AbbVie expands biologics manufacturing in Singapore with US$223 mn investment
AbbVie, a US pharmaceutical company, is investing $223 million in expanding its manufacturing facility in Singapore’s Tuas Biomedical Park. This expansion is expected to create over 100 jobs and increase biologics manufacturing capacity by 24,000 liters. The Singapore plant, serving global markets, focuses on small-molecule and biologics manufacturing. The investment supports AbbVie’s immunology and oncology compounds and strengthens its global manufacturing capabilities. With a decade-long partnership with the Singapore government, AbbVie has invested over $740 million in its Singapore facility. The expanded site, operational in 2026, will employ over 500 people, contributing to Singapore’s advanced manufacturing ecosystem.
Category: Pharmaceuticals
Subscribe
If you enjoyed this article, subscribe to receive more just like it.
